Safety and Immunogenicity, Inactivated Split Influenza Vaccine, Using the Strain Composition 2010/2011

Novartis

Status and phase: Completed; Phase 3

Conditions: Seasonal Influenza

Treatments: Biological: BEGRIVAC

Study type: Interventional

Funder types: Industry

Identifiers

NCT01147081

V44_14S

2010-018371-18

Details and patient eligibility

About

Annual trial for registration influenza vaccine Begrivac with strain composition for season 2010/2011.

Full description

At enrolment, subjects were stratified into two age strata (18 to 60 years, over 60 years). Total duration of the study is three weeks. Vaccinations were to be administered on day 1. Blood samples were collected at day 1 (baseline, before the vaccination) and at day 22 (three weeks after the vaccination). Sera were tested by Hemagglutination Inhibition (HI) assay. Safety was assessed until 3 weeks after the vaccination.

Enrollment: 142 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Male and female volunteers of 18 years of age and older, mentally competent, willing and able to give written informed consent prior to study entry;
2. Individuals able to comply with all the study requirements;
3. Individuals in good health as determined by medical history, physical examination and clinical judgment of the investigator.

Written informed consent must be obtained for all the subjects before enrollment into the study after the nature of the study has been explained.

Exclusion criteria

1. Individuals with behavioral or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may interfere with the subject's ability to participate in the study;

2. Individuals with any serious chronic or acute disease (in the judgment of the investigator), including but not limited to:

   1. Cancer, except for localized skin cancer;
   2. Advanced congestive heart failure;
   3. Chronic obstructive pulmonary disease (COPD);
   4. Autoimmune disease (including rheumatoid arthritis);
   5. Acute or progressive hepatic disease;
   6. Acute or progressive renal disease;
   7. Severe neurological or psychiatric disorder;
   8. Severe asthma;

3. Individuals with history of any anaphylactic reaction and/or serious allergic reaction following a vaccination, a proven hypersensitivity to any component of the study vaccine (e.g. to ovalbumin, chicken protein, chicken feathers, influenza viral protein, Polymyxin B;

4. Individuals with known or suspected (or have a high risk of developing) impairment/alteration of immune function (excluding that normally associated with advanced age) resulting, for example, from:

   1. receipt of immunosuppressive therapy (any parenteral or oral corticosteroid or cancer chemotherapy/radiotherapy) within the past 60 days and for the full length of the study;
   2. receipt of immunostimulants;
   3. receipt of parenteral immunoglobulin preparation, blood products and/or plasma derivates within the past 3 months and for the full length of the study;
   4. suspected or known HIV infection or HIV-related disease;

5. Individuals with known or suspected history of drug or alcohol abuse;

6. Individuals with a bleeding diathesis or conditions associated with prolonged bleeding time that in the investigator's opinion would interfere with the safety of the subject;

7. Female who are pregnant or nursing (breastfeeding) mothers or females of childbearing age do not plan to use acceptable birth control measures, for the duration of the study. Adequate contraception is defined as hormonal (e.g., oral, injection, transdermal patch, implant, cervical ring), barrier (e.g., condom with spermicide or diaphragm with spermicide),,intrauterine device (IUD), or monogamous relationship with vasectomized partner who has been vasectomized for 6 months or more prior to the subject's study entry;

8. Individuals who are not able to comprehend and to follow all required study procedures for the whole period of the study;

9. Individuals that within the past 12 months have received more than one injection of influenza vaccine;

10. Individuals that within the past 6 months have:

    1. had laboratory confirmed seasonal or pandemic influenza disease;
    2. received seasonal or pandemic influenza vaccine;

11. Individuals with any acute or chronic infections requiring systemic antibiotic treatment or antiviral therapy within the last 7 days

12. Individuals that have experienced fever (i.e., axillary temperature ≥ 38°C) within the last 3 days of intended study vaccination

13. Individuals participating in any clinical trial with another investigational product 4 weeks prior to first study visit or intent to participate in another clinical study at any time during the conduct of this study.

14. Individuals who received any other vaccines within 4 weeks prior to enrollment in this study or who are planning to receive any vaccine within 4 weeks from the study vaccines

15. Individuals who have received blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation in the past 12 weeks and for the full length of the study

16. Individuals who are part of study personnel or close family members conducting this study.

17. Individuals with history or any illness that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subjects due to participation in the study.

18. BMI > 35 kg/m2

Trial design

Primary purpose: Prevention

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

142 participants in 1 patient group

Arm 1

Experimental group

Treatment:

Biological: BEGRIVAC